You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer

Article info

Article menu
Immunotherapy biomarkers
Original research
Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer

Authors

  • Zhenghang Wang Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Qi Zhang Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Changsong Qi Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Yuezong Bai Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Feilong Zhao Medical Affairs, 3D Medicines Inc, Shanghai, China PubMed articlesGoogle scholar articles
  • Hui Chen Medical Affairs, 3D Medicines Inc, Shanghai, China PubMed articlesGoogle scholar articles
  • Zhongwu Li Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Xicheng Wang Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Mifen Chen Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Jifang Gong Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Zhi Peng Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Xiaotian Zhang Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Jinping Cai Medical Affairs, 3D Medicines Inc, Shanghai, China PubMed articlesGoogle scholar articles
  • Shiqing Chen Medical Affairs, 3D Medicines Inc, Shanghai, China PubMed articlesGoogle scholar articles
  • Xiaochen Zhao Medical Affairs, 3D Medicines Inc, Shanghai, China PubMed articlesGoogle scholar articles
  • Lin Shen Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Jian Li Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China PubMed articlesGoogle scholar articles

Citation

Wang Z, Zhang Q, Qi C, et al
Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
Journal for ImmunoTherapy of Cancer 2022;10:e004703. doi: 10.1136/jitc-2022-004703
Online issue publication 
January 24, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.